NICE UK approves Roche's PD-L1 mono-antitecentriq for treatment of triple-negative breast cancer
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Following Roche's 'improved offer', NICE UK now supports the combination of PD-L1 mono-antitecentriq (atezolizumab) and nab-yew alcohol for PD-L1-positive advanced triple-negative breast cancerTecentriq has become the first immunotherapy specifically for triple-negative breast cancer, with a surface PD-L1 expression ratio of 1% or higher, no previousbreast chemotherapy (which has spread to other parts of the body) and no surgical removalthe drug helps patients attack cancer by blocking the activity of cancer cells PD-L1PD-L1 is expressed more on the surface of cancer cells than normal cellsincreased the time before the disease worsened by about 2.5 months (5.0 months and 7.5 months, respectively) compared to placebo plus nab-sephol
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
